KR101714370B1 - Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Punicalagin - Google Patents
Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Punicalagin Download PDFInfo
- Publication number
- KR101714370B1 KR101714370B1 KR1020140159911A KR20140159911A KR101714370B1 KR 101714370 B1 KR101714370 B1 KR 101714370B1 KR 1020140159911 A KR1020140159911 A KR 1020140159911A KR 20140159911 A KR20140159911 A KR 20140159911A KR 101714370 B1 KR101714370 B1 KR 101714370B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- present
- prostate
- food
- prostatic hyperplasia
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 title claims abstract description 7
- 230000002265 prevention Effects 0.000 title claims abstract description 6
- 229920000241 Punicalagin Polymers 0.000 title claims abstract description 5
- ZJVUMAFASBFUBG-OGJBWQGYSA-N punicalagin Chemical compound C([C@H]1O[C@@H]([C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]2[C@@H]1OC(=O)C1=CC(O)=C(O)C(O)=C11)O)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(OC3=O)C4=C2C(=O)OC2=C4C3=C1C(O)=C2O ZJVUMAFASBFUBG-OGJBWQGYSA-N 0.000 title claims abstract description 5
- LMIBIMUSUFYFJN-RSVYENFWSA-N punicalagin Natural products O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)cc5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@@H]9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)O[C@@H]19 LMIBIMUSUFYFJN-RSVYENFWSA-N 0.000 title claims abstract description 5
- ZRKSVMFLACVUIU-UHFFFAOYSA-N punicalagin isomer Natural products OC1=C(O)C(=C2C3=4)OC(=O)C=4C4=C(O)C(O)=C3OC(=O)C2=C1C1=C(O)C(O)=C(O)C=C1C(=O)OC1C2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(O)OC1COC(=O)C1=CC4=C(O)C(O)=C1O ZRKSVMFLACVUIU-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 210000002307 prostate Anatomy 0.000 title abstract description 22
- 206010020718 hyperplasia Diseases 0.000 title 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 19
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 206010051482 Prostatomegaly Diseases 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 235000009200 high fat diet Nutrition 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 description 1
- 229960003996 chlormadinone Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003198 tamsulosin hydrochloride Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 푸니칼라진(punicalagin)을 유효성분으로 함유하는 전립선 비대증의 예방 또는 치료용 약학적 조성물, 식품 조성물 및 건강기능식품에 관한 것으로, 본 발명에 따른 푸니칼라진은 전립선 무게 감소 효과가 우수하므로, 이를 유효성분으로 함유하는 전립선 비대증의 예방 또는 치료용 약학적 조성물, 식품 조성물 및 건강기능식품으로 사용할 수 있다.The present invention relates to a pharmaceutical composition, a food composition and a health functional food for the prevention or treatment of benign prostatic hyperplasia comprising punicalagin as an active ingredient. The present invention relates to a pharmaceutical composition, food composition and health functional food, Therefore, it can be used as a pharmaceutical composition, a food composition and a health functional food for preventing or treating the enlargement of the prostate gland containing it as an active ingredient.
Description
본 발명은 푸니칼라진을 유효성분으로 함유하는 전립선 비대증 예방 또는 치료용 약학적 조성물, 식품 조성물 및 건강기능식품에 관한 것이다.
The present invention relates to a pharmaceutical composition, a food composition and a health functional food for preventing or treating enlargement of the prostate gland containing a pynicolazine as an active ingredient.
최근 식생활의 서구화, 근육활동 양의 감소, 그리고 평균 수명의 증가로 인하여 전립선 비대증이나 전립선암과 같은 전립선 질환이 크게 증가하고 있다. 전립선 비대증 발병인구는 50세 이상 남성의 50%, 60세 이상 남성의 60%, 85세 이상 남성의 90%로 나타냈으며, 전립선암은 국내 평균 발병률이 30~40%로 최근 5년간 300%나 급증한 것으로 보고된바 있다(한국식품영양과학회 국제 심포지엄 및 정기학술대회, 2010).Recent westernization of diet, decreased muscle activity, and increased life expectancy have led to a significant increase in prostate diseases such as benign prostatic hyperplasia and prostate cancer. The incidence of prostate hypertrophy was 50% of males aged 50 or older, 60% of males aged 60 or older, and 90% of males aged 85 or older. The average incidence of prostate cancer was 30-40% (International Symposium on Food and Nutrition Science, 2010).
전립선 비대증(benign prostate hyperplasia: BPH)은 전립선이 양성으로 비대해지는 증상으로, 요도 주변의 전립선의 전이 구역에 생기는 양성 선종(adenoma)이다. 전립선 비대증 환자는 전립선 비대에 따른 방광출구폐색(bladder outlet obstruction)으로 인한, 배뇨 후 증상과 같은 하부요로증상(lower uninary tract symptoms: LUTS)이 나타난다. 전립선 비대증은 나이에 따른 전립선 성장의 자연적 진행의 결과로서, 증가된 전립선 세포 증식의 결과 또는 전립선 세포 크기 증가의 결과일 수 있다.Benign prostate hyperplasia (BPH) is a benign prostate hyperplasia that is a benign adenoma in the metastatic area of the prostate around the urethra. Patients with enlarged prostate gland exhibit lower uninary tract symptoms (LUTS) due to bladder outlet obstruction due to enlarged prostate. Prostatic hypertrophy may be the result of increased prostate cell proliferation or increased prostate cell size as a result of the natural progression of prostate growth over time.
이러한 전립선 비대증의 주요 원인으로 서구형 식습관이 지목되고 있으나, 이의 정확한 발병 기전은 아직 밝혀지지 않았다.The main cause of the enlarged prostate is the western type eating habit, but its precise mechanism has not yet been clarified.
현재 전립선 비대증을 치료하기 위한 방법으로는, 피나스테라이드(finasteride) 투여 등의 호르몬 치료법과 전립선 경요도 절제술(transurethral resection of prostate: TURP) 등의 수술적 방법이 이용되고 있다. 그러나, 이들 방법은 발기부전 등의 부작용이 나타나는 것으로 알려져 있다.Currently, hormonal therapy such as finasteride and surgical methods such as transurethral resection of prostate (TURP) are used as methods for treating enlargement of the prostate. However, these methods are known to cause side effects such as erectile dysfunction.
최근에는 동백오일을 발효시켜 제조된 발효 동백오일을 함유하는 전립선 비대증 개선용 약제(대한민국 등록특허 제10-1452320호), 익지인 추출물을 함유하는 전립선암 치료용 조성물(대한민국 등록특허 제10-1385658호) 등이 개발된바 있다.Recently, a composition for treating hyperplasia of prostate (Korean Patent No. 10-1452320) containing a fermented camellia oil prepared by fermenting camellia oil (Korean Patent No. 10-1452320) and a composition for treating prostate cancer containing extract of Chinese primate (Korean Patent No. 10-1385658 Has been developed.
아울러, 양성 전립선 비대증에 기인한 방광폐색에 효과적이라고 인식되어 잇는, 탐술로신(tamsulosin) 히드로클라이드 등의 α1-수용체 차단제, 클로르마디논(chlormadinon) 아세테이트 등의 항안드로겐제, 식물성 제제 등이 전립선 비대증 치료제로 사용되고 있으나, 이들의 방광폐색의 개선효과가 불충분하여 대량투여가 불가피하다는 단점이 있다.
In addition, α1-receptor blockers such as tamsulosin hydrochloride, which are recognized to be effective for bladder occlusion caused by benign prostatic hyperplasia, antiandrogens such as chlormadinon acetate, and vegetable agents, They are used as therapeutic agents for hypertrophy, but their effect of improving bladder occlusion is insufficient, which is a disadvantage in that a large dose administration is inevitable.
이에 본 발명자들은 전립선 비대증에 유효한 물질에 대해 지속적인 연구를 하였으며, 푸니칼라진이 전립선 무게 감소 효과가 있음을 밝혀내어 본 발명을 완성하였다.
Accordingly, the present inventors have conducted continuous research on substances effective for enlargement of the prostate gland, and have found that the punicolazine has an effect of reducing prostate weight, thus completing the present invention.
본 발명의 목적은 전립선 무게 감소에 효과가 있는 푸니칼라진을 유효성분으로 함유하는 전립선 비대증의 예방 또는 치료용 약학적 조성물, 식품 조성물 및 건강기능식품을 제공하는데 그 목적이 있다.
It is an object of the present invention to provide a pharmaceutical composition, a food composition and a health functional food for the prevention or treatment of benign prostatic hyperplasia comprising an effective amount of ponikalazine as an effective ingredient for reducing prostate weight.
상기 목적을 달성하기 위하여, 본 발명은 푸니칼라진(punicalagin)을 유효성분으로 함유하는 전립선 비대증의 예방 또는 치료용 약학적 조성물을 제공한다. 상기 전립선 비대증은 비만 유래 전립선 비대증일 수 있고, 상기 조성물은 캡슐, 정제, 과립, 분말 또는 음료 형태가 가능하다.
In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating enlargement of the prostate gland containing punicalagin as an active ingredient. The enlarged prostate gland may be obesity-induced enlarged prostate gland, and the composition may be in the form of a capsule, tablet, granule, powder or beverage.
나아가, 본 발명은 푸니칼라진을 유효성분으로 함유하는 전립선 비대증의 예방 또는 증상완화용 식품 조성물을 제공한다. 상기 전립선 비대증은 비만 유래 전립선 비대증일 수 있고, 상기 건강기능식품은 캡슐, 정제, 과립, 분말 또는 음료 형태가 가능하다.
Further, the present invention provides a food composition for the prevention or symptomatic relief of benign prostatic hyperplasia which comprises as an active ingredient a pynicolazin. The benign prostatic hyperplasia may be obesity-induced enlarged prostate, and the health functional food may be in the form of capsules, tablets, granules, powders or beverages.
본 발명에서 푸니칼라진은 하기 화학식 1과 같이 나타낸다.In the present invention, the punikyrazine is represented by the following general formula (1).
본 발명에서 푸니칼라진은 추출 또는 합성에 의하여 얻을 수 있다. 본 발명의 일 실시예에서는 AK Scientific사에서 구입한 푸니칼라진(제품번호 V1526, 순도 40%)을 사용하였으나, 이에 한정되는 것은 아니다.In the present invention, the punicolazine can be obtained by extraction or synthesis. In one embodiment of the present invention, ponikalazine purchased from AK Scientific (product number V1526, purity: 40%) was used, but the present invention is not limited thereto.
본 발명의 조성물은, 조성물 총 중량에 대하여 상기 푸니칼라진을 0.1 내지 50 중량%로 포함한다. 본 발명의 푸니칼라진을 포함하는 조성물은 통상의 방법에 따른 적절한 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. 본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 본 발명에 따른 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 상세하게는, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 푸니칼라진에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스 (sucrose), 락토오스 (lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The composition of the present invention is characterized in that the above-mentioned < RTI ID = 0.0 > 0.1 to 50% by weight. The composition comprising the pynicolazine of the present invention may further comprise suitable carriers, excipients or diluents according to conventional methods. Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols or the like, oral preparations, suppositories or sterilized injection solutions according to a conventional method have. More specifically, when formulating the composition, it can be prepared using a diluent or an excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, and the like. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, (sucrose), lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, syrups and the like. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances and preservatives . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
본 발명은 환자의 나이, 성별, 체중에 따라 달라질 수 있으나, 일반적으로 0.01 내지 500 mg/㎏의 양, 바람직하게는 0.1 내지 100 mg/㎏의 양을 일일 1회 내지 수회로 나누어 투여할 수 있다. 또한 그 투여량은 투여경로, 질병의 정도, 성별, 체중, 나이 등에 따라서 증감될 수 있다. 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The present invention may be varied depending on the age, sex and body weight of the patient, but it is generally administered in an amount of 0.01 to 500 mg / kg, preferably 0.1 to 100 mg / kg, once to several times per day . The dosage may also be increased or decreased depending on the route of administration, degree of disease, sex, weight, age, and the like. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.
본 발명의 조성물은 랫트, 마우스, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식이 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌실내 (intracerebroventricular) 주사에 의해 투여될 수 있다. 본 발명의 푸니칼라진은 독성 및 부작용은 거의 없으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다. The composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections. Since the fungicolin of the present invention has little toxicity and side effects, it can be safely used for prolonged use for preventive purposes.
본 발명은 상기 식품 조성물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강기능식품을 제공하는데, 각종 식품류, 예를 들어, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있으며, 환제, 분말, 과립, 침제, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다. 이때, 식품 또는 음료 중의 상기 푸니칼라진의 양은, 일반적으로 본 발명의 건강식품 조성물의 경우 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강음료 조성물의 경우 100 ㎖를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.The present invention provides a health functional food comprising the above food composition and a pharmaceutically acceptable food supplementary additive. The present invention includes various foods such as beverages, gums, tea, vitamin complexes, health supplement foods, Powders, granules, precipitates, tablets, capsules or beverages. At this time, the amount of the punicolazine in the food or drink may generally be 0.01 to 15% by weight of the total food weight of the health food composition of the present invention, 0.02 to 10 g , Preferably 0.3 to 1 g.
본 명세서에서 정의되는 식품보조첨가제는 당업계에 통상적인 식품첨가제, 예를 들어 향미제, 풍미제, 착색제, 충진제, 안정화제 등을 포함한다. 본 발명에 따른 건강음료 조성물은 지시된 비율로 필수 성분으로서, 상기 푸니칼라진 외에 첨가되는 성분에 특별한 제한은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물의 예로는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린; 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제 (타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등)) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12g이다.Food supplementary additives as defined herein include food additives customary in the art, such as flavoring agents, flavoring agents, coloring agents, fillers, stabilizers, and the like. The health beverage composition according to the present invention may contain, as an essential ingredient at the indicated ratio, the ingredient to be added in addition to the above-mentioned pinicolazin, and it may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages . Examples of the natural carbohydrate include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; Polysaccharides such as dextrin, cyclodextrins; And sugar alcohols such as xylitol, sorbitol, and erythritol. As natural flavors other than those described above, natural flavors (such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin)) and synthetic flavors (saccharin, aspartame, etc.) have. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
이상에서 설명한 바와 같이, 본 발명에 따른 푸니칼라진은 전립선 무게 감소 효과가 우수하므로, 이를 유효성분으로 함유하는 전립선 비대증의 예방 또는 치료용 약학적 조성물과 건강기능식품으로 사용할 수 있다.
INDUSTRIAL APPLICABILITY As described above, the present invention can be used as a pharmaceutical composition and a health functional food for the prevention or treatment of benign prostatic hyperplasia containing the active ingredient of the present invention.
도 1은 정상 사료를 섭취한 군(ND), 고지방 사료를 섭취한 군(HFD) 및 고지방 사료와 푸니칼라진을 동시에 투여한 군(DM)의 혈중 GOT를 측정한 결과를 나타낸 그래프이다.FIG. 1 is a graph showing the results of measurement of blood GOT in a group (ND) fed with a normal diet, a group fed with a high fat diet (HFD), and a group administered with a high fat diet and a funicillin group simultaneously (DM).
이하, 본 발명을 하기의 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are illustrative of the present invention, and the contents of the present invention are not limited by the following examples.
실시예Example
실시예Example 1. 푸니칼라진 1. Ponycalla Jin 의of 전립선 무게 감소 효과 측정 Measure prostate weight reduction effect
푸니칼라진의 전립선 비대증 예방 또는 치료 효과를 검증하기 위하여, 푸니칼라진의 처리에 따른 전립선 무게 변화를 측정하였다. In order to test the efficacy of pneumocarazine for prophylactic or prophylactic treatment of prostate enlargement, we measured the change in prostate weight by treatment with ponikalazine.
푸니칼라진은 AK Scientific사에서 구입하여 사용하였다(제품번호 V1526, 순도 40%).The pony color gel was purchased from AK Scientific (product number V1526, purity 40%).
4주령의 수컷 마우스(C57BL/6)를 1주일 동안 적응시킨 뒤 실험동물로 사용하였다. 실험동물을 세 개의 군으로 나누어, 첫 번째 군(ND)은 정상 사료(10% 지방 칼로리 사료; Research Diet사 제품번호 D12450B)를 섭취하도록 하였고, 두 번째 군(HFD)은 고지방 사료(60% 지방 칼로리 사료; Research Diet사 제품번호 D12492)를 섭취하도록 하였고, 세 번째 군(DIM)은 고지방 사료 섭취와 동시에 푸니칼라진을 쥐 무게(kg) 당 40 mg의 농도로 실험 식이에 섞어 섭취하도록 하였다(사료에 400 mg/kg (0.04%)의 농도로 섞어 제공). 실험 식이는 자유 식이로 80일간 제공하였다. 실험동물을 사육한 후에, 실험동물을 희생하여 전립선의 무게를 측정하였다.Four-week-old male mice (C57BL / 6) were adapted for one week and used as experimental animals. The second group (HFD) was fed high fat diets (60% fat, 100% fat), and the first group (ND) received normal diet (10% fat calorie diet; Research Diet D12450B) The third group (DIM) was fed with high-fat diets at the same time as the pigs fed the experimental diet with 40 mg per kg weight of pigs (kg) Feed mixed with a concentration of 400 mg / kg (0.04%)). The experimental diet was given for 80 days as a free diet. After raising the experimental animals, the prostate weight was measured by sacrificing the experimental animals.
그 결과, 첫 번째 군(ND)과 두 번째 군(HFD)의 전립선 무게는 각각 21.9mg과 48.1mg으로, 고지방 식이에 의하여 약 2.2배 증가하였음을 알 수 있었다. 그러나, 푸니칼라진을 함께 섭취한 세 번째 군(PG)의 전립선 무게는 27.6mg으로, 두 번째 군(HFD)에 비해 약 43% 감소하였음을 알 수 있었다(표 1).As a result, the prostate weights of the first group (ND) and the second group (HFD) were 21.9 mg and 48.1 mg, respectively, which was about 2.2 times higher by the high fat diet. However, the prostate weight of the third group (PG), which received the pinnycholamine, was 27.6 mg, which was about 43% lower than the second group (HFD) (Table 1).
N≥8, one-way ANOVA, poset hoc tests: Duncan
N ≥ 8, one-way ANOVA, poset hoc tests: Duncan
실시예Example 2. 푸니칼라진 2. Ponycalla Jin 의of 독성 검사 Toxicity test
임상 및 식품에 이용하기 위하여 독성 검사를 실시하였다. 간의 독성 지표인 혈중 GOT(glutamic oxaloacetic transaminase)를 측정한 결과, ND군은 78 Karmen/ml, HFD군은 82 Karmen/ml, PG군은 74 Karmen/ml로, 푸니칼라진이 독성을 유발하지 않음을 알 수 있었다(도 1).
Toxicity tests were performed for clinical and food use. As a result of measurement of the serum GOT (glutamic oxaloacetic transaminase) as the index of toxicity of the liver, the PN group showed 78 Karmen / ml, the HFD group had 82 Karmen / ml and the PG group had 74 Karmen / (Fig. 1).
지금까지 예시적인 실시 태양을 참조하여 본 발명을 기술하여 왔지만, 본 발명이 속하는 기술 분야의 당업자는 본 발명의 범주를 벗어나지 않고서도 다양한 변화를 실시할 수 있으며, 그의 요소들을 등가물로 대체할 수 있음을 알 수 있을 것이다. 또한, 본 발명의 본질적인 범주를 벗어나지 않고서도 많은 변형을 실시하여 특정 상황 및 재료를 본 발명의 교시내용에 채용할 수 있다. 따라서, 본 발명이 본 발명을 실시하는데 계획된 최상의 양식으로서 개시된 특정 실시 태양으로 국한되는 것이 아니며, 본 발명이 첨부된 특허청구의 범위에 속하는 모든 실시 태양을 포함하는 것으로 해석되어야 한다.While the present invention has been described with reference to exemplary embodiments, those skilled in the art will appreciate that various changes and modifications can be made thereto without departing from the scope of the invention, . In addition, many modifications may be made to adapt a particular situation and material to the teachings of the invention without departing from the essential scope thereof. Accordingly, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention be construed as including all embodiments falling within the scope of the appended claims.
Claims (7)
A pharmaceutical composition for the prophylaxis or treatment of prostatic hyperplasia comprising punicalagin as an active ingredient.
The pharmaceutical composition according to claim 1, wherein the prostatic hyperplasia is obesity-derived prostatic hyperplasia.
The pharmaceutical composition according to claim 1, which is in the form of a capsule, tablet, granule, powder or drink, for the prophylaxis or treatment of prostatic hyperplasia.
A food composition for the prevention or symptomatic relief of benign prostatic hyperplasia comprising as an active ingredient punicalagin.
5. The food composition according to claim 4, wherein the enlarged prostate is obesity-derived enlarged prostate.
5. A food composition according to claim 4, which is in the form of a capsule, tablet, granule, powder or beverage, for the prophylaxis or symptomatic relief of benign prostatic hyperplasia.
A health functional food for preventing or symptomatic relief of benign prostatic hyperplasia comprising the food composition of any one of claims 4 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140159911A KR101714370B1 (en) | 2014-11-17 | 2014-11-17 | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Punicalagin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140159911A KR101714370B1 (en) | 2014-11-17 | 2014-11-17 | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Punicalagin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160059028A KR20160059028A (en) | 2016-05-26 |
| KR101714370B1 true KR101714370B1 (en) | 2017-03-10 |
Family
ID=56104479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140159911A KR101714370B1 (en) | 2014-11-17 | 2014-11-17 | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Punicalagin |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101714370B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200089420A (en) | 2019-01-17 | 2020-07-27 | 군산대학교산학협력단 | Voratin isolated from Symbiodinium voratum and composition for preventing, improving or treating benign prostatic hyperplasia comprising the same as an effective ingredient |
| KR102296821B1 (en) | 2020-06-23 | 2021-09-01 | 군산대학교 산학협력단 | Extract of Symbiodinium voratum and composition for preventing, improving or treating benign prostatic hyperplasia comprising the same as an effective ingredient |
| KR20210158024A (en) | 2020-06-23 | 2021-12-30 | 군산대학교산학협력단 | Novel compound Ovataline isolated from Ostreopsis cf. ovata and composition for preventing, improving or treating benign prostatic hyperplasia comprising the same as an effective ingredient |
| KR20230087142A (en) | 2021-12-09 | 2023-06-16 | 군산대학교산학협력단 | Composition for preventing, improving or treating benign prostatic hyperplasia and alopecia comprising Voratin isolated from Symbiodinium voratum and as an effective ingredient |
| RU2812292C1 (en) * | 2022-09-09 | 2024-01-29 | Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" | Antiviral agent against tick-borne encephalitis virus |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254223A (en) | 2008-03-04 | 2008-09-03 | 东莞市竟恒流通研究所 | Pomegranate rind and novel method for improving prostate gland symptoms with carthaginian apple seed extract |
| WO2013016144A1 (en) | 2011-07-22 | 2013-01-31 | Pom Wonderful, Llc | Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith |
-
2014
- 2014-11-17 KR KR1020140159911A patent/KR101714370B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254223A (en) | 2008-03-04 | 2008-09-03 | 东莞市竟恒流通研究所 | Pomegranate rind and novel method for improving prostate gland symptoms with carthaginian apple seed extract |
| WO2013016144A1 (en) | 2011-07-22 | 2013-01-31 | Pom Wonderful, Llc | Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith |
Non-Patent Citations (2)
| Title |
|---|
| Evidence-Based Complementary and Alternative Medicine. 2013. Vol.2013, Article ID 701434.* |
| Food Chemistry. 2012. Vol.132, pp.1585-1591.* |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200089420A (en) | 2019-01-17 | 2020-07-27 | 군산대학교산학협력단 | Voratin isolated from Symbiodinium voratum and composition for preventing, improving or treating benign prostatic hyperplasia comprising the same as an effective ingredient |
| KR102296821B1 (en) | 2020-06-23 | 2021-09-01 | 군산대학교 산학협력단 | Extract of Symbiodinium voratum and composition for preventing, improving or treating benign prostatic hyperplasia comprising the same as an effective ingredient |
| KR20210158024A (en) | 2020-06-23 | 2021-12-30 | 군산대학교산학협력단 | Novel compound Ovataline isolated from Ostreopsis cf. ovata and composition for preventing, improving or treating benign prostatic hyperplasia comprising the same as an effective ingredient |
| KR20230087142A (en) | 2021-12-09 | 2023-06-16 | 군산대학교산학협력단 | Composition for preventing, improving or treating benign prostatic hyperplasia and alopecia comprising Voratin isolated from Symbiodinium voratum and as an effective ingredient |
| RU2812292C1 (en) * | 2022-09-09 | 2024-01-29 | Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" | Antiviral agent against tick-borne encephalitis virus |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160059028A (en) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101714370B1 (en) | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Punicalagin | |
| EP1618875B1 (en) | Composition for inhibition or prevention of bone density lowering | |
| KR101614574B1 (en) | Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange | |
| KR101902932B1 (en) | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum | |
| KR20180016275A (en) | Food composition and Pharmaceutical composition for activation of anti-oxidant, anti-inflammatory or immunity comprising hot water extract of Angelica gigas nakai, Cnidium officinale makino, Paeonia lactiflora and extract of Red ginseng or extract of Gapi taheebo | |
| KR101552813B1 (en) | Compositions for preventing or treating benign prostatic hyperplasia comprising extracts of Quisqualis indica | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR20160059029A (en) | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Diindolylmethane | |
| KR20160016280A (en) | Composition for immune enhancement comprising taheebo extract or ginseng leaf extract | |
| KR20170054116A (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
| KR20160114841A (en) | Composition for improvement or treatment of Fat comprising Eucommiae ulmoides Oliv. Bark. extract or Adiponectin isolated therefrom as active ingredient | |
| KR101641415B1 (en) | Composition comprising the combined extracts of Phlomis umbrosa, Astragalus membranceus, Discorea japonica, Acanthpanax senticosus and Angelica gigas for stimulating bone growth | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| KR20210158833A (en) | Composition comprising extract of Rehmannia for preventing or treating prostate-related disease | |
| KR20180086935A (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
| KR101597187B1 (en) | A composition comprising the extract of Melia azedarach showing anti-cancer activity against stomach tumor | |
| KR101026523B1 (en) | Pharmaceutical composition and food additives containing extract of black onion for prevention and treatment of overweight or obesity | |
| KR20210140933A (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
| KR101787458B1 (en) | Composition comprising extract of Myristica fragrans Houtt for treating or preventing endometriosis | |
| KR20150124108A (en) | Food and pharmaceutical composition for preventing or improving obesity comprising Curcuma longa extract as effective component | |
| KR100888068B1 (en) | Compositions for suppressing obesity | |
| KR20150048495A (en) | Pharmaceutical composition comprising Cistanche deserticola extracts for preventing and treating prostatic hyperplasia | |
| KR101684574B1 (en) | Pharmaceutical compositions and health functional foods comprising Cibotium barometz J. Smith extracts for preventing or treating anticancer agent-induced of hematopoietic toxicity | |
| KR101620160B1 (en) | Composition for the prevention or treatment of Inflammatory Bowel Disease comprising extract of Atractylodes spp, and Poncirus trifoliata | |
| KR101293032B1 (en) | Pharmaceutical composition for treating or preventing obesity comprising sea tangle and sodium butyrate as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 4 |